Tezepelumab对中重度未控制哮喘气道炎症、重塑及高反应性的影响(CASCADE):双盲随机安慰剂对照2期试验
CASCADE探索性2期试验纳入116例中重度未控制哮喘患者,随机接受Tezepelumab 210 mg或安慰剂皮下注射每4周一次。其他炎症细胞、基底膜厚度及上皮完整性无显著差异。
要点
- Tezepelumab显著降低气道黏膜下嗜酸性粒细胞,各基线血嗜酸性粒细胞亚组一致。
- 其他气道炎症细胞、基底膜厚度及上皮完整性未见显著差异。
- Tezepelumab显著降低甘露醇激发的气道高反应性。
核心结论
- Tezepelumab改善哮喘临床结局可能部分由减少嗜酸性气道炎症驱动,且不依赖基线血嗜酸性粒细胞水平。
- Tezepelumab还降低甘露醇气道高反应性,提示TSLP阻断可能带来超越2型炎症的额外获益。
研究设计与样本
- CASCADE为探索性、双盲、随机、安慰剂对照、平行组2期研究,在加拿大、丹麦、德国、英国和美国27个中心开展。
- 纳入18-75岁中重度未控制哮喘成人,按1:1随机接受Tezepelumab 210 mg或安慰剂皮下注射每4周一次,计划28周,因COVID-19 disruption可延长至52周。
- 随机化按血嗜酸性粒细胞计数分层平衡。
- 共入组250例,随机116例(Tezepelumab组59例,安慰剂组57例)。
- 主要疗效分析纳入完成至少20周治疗且有可评估基线和治疗结束支气管镜活检者(Tezepelumab组48例,安慰剂组51例)。
主要发现
- 网状基底膜厚度和上皮完整性(剥脱、损伤、完整上皮比例)两组无显著差异。
- 不良事件:Tezepelumab组53例(90%)报告不良事件,安慰剂组51例(90%),无安全性担忧发现。
关键数值与推荐
- 主要终点为支气管镜活检样本气道黏膜下炎症细胞数从基线至治疗结束的变化,分别评估嗜酸性粒细胞、中性粒细胞、CD3+ T细胞、CD4+ T细胞、类胰蛋白酶+肥大细胞和糜蛋白酶+肥大细胞。
- 次要终点包括网状基底膜厚度和上皮完整性(剥脱、损伤、完整上皮比例)从基线的变化。
- 探索性结局包括对甘露醇的气道高反应性。
临床怎么用
- 对于中重度未控制哮喘,Tezepelumab可降低气道嗜酸性粒细胞炎症,且效应不依赖基线血嗜酸性粒细胞水平。
- Tezepelumab可能改善气道高反应性,提示其获益不仅限于2型炎症通路。
- 治疗期间不良事件发生率与安慰剂相当,未发现新的安全性信号。
局限性
- 本研究为探索性2期试验,样本量较小,主要终点分析仅纳入48例Tezepelumab组和51例安慰剂组患者。
- 主要终点及气道高反应性分析均为名义显著性,未进行多重比较校正。
- 研究因COVID-19相关干扰允许治疗延长至52周,可能影响治疗时长的一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine. In phase 2b and 3 studies, tezepelumab significantly reduced exacerbations versus placebo in patients with severe uncontrolled asthma, irrespective of baseline levels of type 2 inflammatory biomarkers. We investigated the mechanism of action of tezepelumab by assessing its effects on airway inflammatory cells, airway remodelling, and airway hyperresponsiveness. METHODS: CASCADE was an exploratory, double-blind, randomised, placebo-controlled, parallel-group, phase 2 study done in 27 medical centres in Canada, Denmark, Germany, the UK, and the USA. Adults aged 18-75 years with uncontrolled, moderate-to-severe asthma were randomly assigned (1:1) to receive tezepelumab 210 mg or placebo administered subcutaneously every 4 weeks for a planned 28 weeks, extended to up to 52 weeks if COVID-19-related disruption delayed participants' end-of-treatment assessments. Randomisation was balanced and stratified by blood eosinophil count. The primary endpoint was the change from baseline to the end of treatment in the number of airway submucosal inflammatory cells in bronchoscopic biopsy samples. Eosinophils, neutrophils, CD3+ T cells, CD4+ T cells, tryptase+ mast cells, and chymase+ mast cells were evaluated separately. This endpoint was also assessed in subgroups according to baseline type 2 inflammatory biomarker levels, including blood eosinophil count. Airway remodelling was assessed via the secondary endpoints of change from baseline in reticular basement membrane thickness and epithelial integrity (proportions of denuded, damaged, and intact epithelium). Exploratory outcomes included airway hyperresponsiveness to mannitol. All participants who completed at least 20 weeks of study treatment, had an end-of-treatment visit up to 8 weeks after the last dose of study drug, and had evaluable baseline and end-of-treatment bronchoscopies were included in the primary efficacy analysis. All participants who received at least one dose of study drug were included in the safety analyses. This study is registered with ClinicalTrials.gov, NCT03688074. FINDINGS: Between Nov 2, 2018, and Nov 16, 2020, 250 patients were enrolled, 116 of whom were randomly assigned (59 to tezepelumab, 57 to placebo). 48 in the tezepelumab group and 51 in the placebo group completed the study and were assessed for the primary endpoint. Treatment with tezepelumab resulted in a nominally significantly greater reduction from baseline to the end of treatment in airway submucosal eosinophils versus placebo (ratio of geometric least-squares means 0·15 [95% CI 0·05-0·41]; nominal p<0·0010), with the difference seen across all baseline biomarker subgroups. There were no significant differences between treatment groups in the other cell types evaluated (ratio of geometric least-squares means: neutrophils 1·36 [95% CI 0·94-1·97]; CD3+ T cells 1·12 [0·86-1·46]; CD4+ T cells 1·18 [0·90-1·55]; tryptase+ mast cells 0·83 [0·61-1·15]; chymase+ mast cells 1·19 [0·67-2·10]; all p>0·10). In assessment of secondary endpoints, there were no significant differences between treatment groups in reticular basement membrane thickness and epithelial integrity. In an exploratory analysis, the reduction in airway hyperresponsiveness to mannitol was significantly greater with tezepelumab versus placebo (least-squares mean change from baseline in interpolated or extrapolated provoking dose of mannitol required to induce ≥15% reduction in FEV1 from baseline: tezepelumab 197·4 mg [95% CI 107·9 to 286·9]; placebo 58·6 mg [-30·1 to 147·33]; difference 138·8 [14·2 to 263·3], nominal p=0·030). Adverse events were reported in 53 (90%) patients in the tezepelumab group and 51 (90%) patients in the placebo group, and there were no safety findings of concern. INTERPRETATION: The improvements in asthma clinical outcomes observed in previous studies with tezepelumab are probably driven, at least in part, by reductions in eosinophilic airway inflammation, as shown here by reduced airway eosinophil counts regardless of baseline blood eosinophil count. Tezepelumab also reduced airway hyperresponsiveness to mannitol, indicating that TSLP blockade might have additional benefits in asthma beyond reducing type 2 airway inflammation. FUNDING: AstraZeneca and Amgen.
引用
- Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021. PMID: 34256031. doi:10.1016/S2213-2600(21)00226-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。